A planned live-in residency in Puerto Rico for pharmaceutical manufacturing and biomanufacturing founders — on an island that already makes a quarter of US pharmaceutical exports.
Puerto Rico manufactures a quarter of all US pharmaceutical exports and hosts more than 80,000 pharma professionals — yet has no dedicated biotech founder residency. That gap is the opening.
T
Terrain
A 75-year manufacturing legacy: Amgen, Pfizer, J&J, AbbVie, Eli Lilly, BMS, AstraZeneca, Merck and GSK all operate on the island.
W
Workforce
More than 80,000 pharma and medical-device professionals, 21,000+ STEM graduates a year, bilingual and cGMP-experienced.
R
Regulation
Puerto Rico operates under FDA jurisdiction — the same cGMP standards as the mainland, with no import or export complexity.
F
Federal backing
The PRBio Tech Hub designation in 2023 made the island one of 31 national Tech Hubs, eligible for EDA implementation funding.
PharmHaus
Why now
01
Reshoring imperative
$24.86B of CDMO capacity investment landed in 2025 alone, with roughly 74% of that capital flowing to the United States.
02
Federal investment
PRBio Tech Hub designation is the first national recognition of Puerto Rico's biotech potential.
03
Post-restructuring stability
Public debt was cut by roughly 75%, and the economy has been in positive growth since 2021.
04
Biologics revolution
The biologics CDMO market is growing at roughly 13.7% a year — cell and gene therapy, mRNA, and biosimilars all need new manufacturing.
Not open yet
PharmHaus is in development. Partner agreements, facilities, and program staffing are being put in place, with applications expected to open ahead of the first cohort. If you want to be told when that happens — or want to help build it — email us.
PharmHaus · Puerto Rico
Get in early.
PharmHaus is still being built. Founders, partners, and sponsors who want in early — start here.